Accuray (ARAY) Aktievy
Accuray Incorporated bedriver design, utveckling, tillverkning och försäljning av strålkirurgi- och strålbehandlingssystem för behandling av tumörer i USA, Kanada, Latinamerika, Asien, Australien, Nya Zeeland, Europa, Mellanöstern, Indien, Afrika, Japan och Kina. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
ARAY Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Accuray Incorporated Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$0.33 |
| 52 veckors högsta | US$2.10 |
| 52 veckors lägsta | US$0.22 |
| Beta | 1.39 |
| 1 månads förändring | 25.95% |
| 3 månaders förändring | 14.28% |
| 1 års förändring | -79.84% |
| 3 års förändring | -88.74% |
| 5 års förändring | -91.98% |
| Förändring sedan börsintroduktionen | -98.85% |
Senaste nyheter och uppdateringar
Recent updates
ARAY: Reset P/E Expectations And Guidance Withdrawal Will Shape Future Risk Balance
The analyst price target on Accuray has been cut by about $3.53 to reflect a lower implied fair value, a higher discount rate, and sharply reduced future P/E expectations, following recent downgrades where analysts cited softer growth and margin assumptions. Analyst Commentary Recent research on Accuray has focused on how realistic growth and margin assumptions should feed into valuation, especially after the latest downgrades and the reset in future P/E expectations.Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) Estimates
Today is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...
Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Unfortunately for some shareholders, the Accuray Incorporated ( NASDAQ:ARAY ) share price has dived 33% in the last...Groundhog Day Once Again, As Accuray Misses And Lowers
Summary Accuray continues to disappoint with weaker revenue, weaker orders and market share, lowered guidance, and little evidence of a turnaround. ARAY's restructuring aims for $25M in annual profitability improvements, but lacks novel strategies and may risk further sales declines. Competitive pressure from Siemens Healthineers and Elekta underscores ARAY's inability to gain traction, especially in critical markets like China. Despite undervaluation, persistent cash burn and lack of turnaround visibility make the risk/reward unattractive; I plan to exit my small position. Read the full article on Seeking Alpha
Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding
The Accuray Incorporated ( NASDAQ:ARAY ) share price has fared very poorly over the last month, falling by a...Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price
Accuray Incorporated's ( NASDAQ:ARAY ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Returns At Accuray (NASDAQ:ARAY) Are On The Way Up
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 0.3x Accuray Incorporated ( NASDAQ:ARAY ) may be sending very bullish signals...Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a horrible month, losing 26% after a relatively good period...Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a really impressive month, gaining 25% after a shaky period...Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Summary Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. Accuray appears undervalued but faces significant risks; the potential for better results exists, particularly if China efforts succeed and U.S. sales stabilize, but improvement in execution has long been elusive. Read the full article on Seeking AlphaHealth Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Accuray Incorporated: Cheap, But With Caveats
Summary Today, we take a deeper look at Accuray Incorporated, a medical device company that manufactures radiosurgery and radiation therapy systems. Despite mid-single-digit sales growth, Accuray trades at under 50% of current revenues and is nearing profitability, but the company has a significant debt load. A couple of analyst firms believe the stock should be trading at much higher levels. An analysis around Accuray Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaAccuray Remains A Perpetual 'Next Year Is Our Year' Story
Summary Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful. Execution remains critical as the company faces tough competition and needs to capitalize on growth opportunities in China and replacement/renewal opportunities in the U.S. market. Accuray shares offer potential upside, at the cost of elevated risk, if the company can overcome sales execution challenges and capitalize on emerging market opportunities. Read the full article on Seeking AlphaAccuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues
Accuray Incorporated ( NASDAQ:ARAY ) shareholders won't be pleased to see that the share price has had a very rough...Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop
To the annoyance of some shareholders, Accuray Incorporated ( NASDAQ:ARAY ) shares are down a considerable 25% in the...Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results
It's shaping up to be a tough period for Accuray Incorporated ( NASDAQ:ARAY ), which a week ago released some...Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Accuray fair value estimate is US$2.06 Accuray's US$1.54 share...Aktieägarnas avkastning
| ARAY | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | 11.7% | -0.4% | 0.1% |
| 1Y | -79.8% | -12.4% | 18.9% |
Avkastning vs industri: ARAY presterade sämre än US Medical Equipment branschen som gav -12.4 % under det senaste året.
Avkastning vs Marknaden: ARAY presterade sämre än US marknaden som gav 18.9 % under det senaste året.
Prisvolatilitet
| ARAY volatility | |
|---|---|
| ARAY Average Weekly Movement | 16.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: ARAY s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ARAY s veckovolatilitet ( 17% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1990 | 990 | Steve LaNeve | www.accuray.com |
Accuray Incorporated bedriver design, utveckling, tillverkning och försäljning av strålkirurgi- och strålterapisystem för behandling av tumörer i USA, Kanada, Latinamerika, Asien, Australien, Nya Zeeland, Europa, Mellanöstern, Indien, Afrika, Japan och Kina. Bolaget erbjuder CyberKnife-plattformen, ett robotiserat system för stereotaktisk strålkirurgi och stereotaktisk kroppsstrålbehandling som används för behandling av primära och metastatiska tumörer utanför hjärnan, inklusive tumörer på eller nära ryggraden samt i bröst, njure, lever, lunga, bukspottkörtel och prostata. Företaget tillhandahåller även TomoTherapy-plattformen, inklusive Radixact System, som möjliggör integrerad planering, leverans och datahantering av strålbehandling, vilket gör det möjligt för kliniker att leverera ultraprecisa behandlingar till cirka 50 patienter per dag; iDMS data management system, ett helt integrerat system för behandlingsplanering och datahantering; och Accuray precision treatment planning system, ett system för behandlingsplanering och datahantering.
Accuray Incorporated Sammanfattning av grunderna
| ARAY grundläggande statistik | |
|---|---|
| Börsvärde | US$33.10m |
| Vinst(TTM) | -US$46.13m |
| Intäkter(TTM) | US$428.57m |
Är ARAY övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ARAY resultaträkning (TTM) | |
|---|---|
| Intäkter | US$428.57m |
| Kostnad för intäkter | US$313.22m |
| Bruttovinst | US$115.36m |
| Övriga kostnader | US$161.49m |
| Intäkter | -US$46.13m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 19, 2026
| Vinst per aktie (EPS) | -0.39 |
| Bruttomarginal | 26.92% |
| Nettovinstmarginal | -10.76% |
| Skuld/egenkapitalförhållande | 348.1% |
Hur har ARAY utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/17 17:38 |
| Aktiekurs vid dagens slut | 2026/08/17 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/06/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Accuray Incorporated bevakas av 16 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |